• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Cerebral Infarction (Brain Infarction) - Pipeline Review, H2 2012 Product Image

Cerebral Infarction (Brain Infarction) - Pipeline Review, H2 2012

  • ID: 2366237
  • December 2012
  • 33 pages
  • Global Markets Direct

Cerebral Infarction (Brain Infarction) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Cerebral Infarction (Brain Infarction) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cerebral Infarction (Brain Infarction), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cerebral Infarction (Brain Infarction). Cerebral Infarction (Brain Infarction) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cerebral Infarction READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Cerebral Infarction (Brain Infarction) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Cerebral Infarction (Brain Infarction) 7
Cerebral Infarction (Brain Infarction) Therapeutics under Development by Companies 9
Cerebral Infarction (Brain Infarction) Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Cerebral Infarction (Brain Infarction) Therapeutics – Products under Development by Companies 14
Cerebral Infarction (Brain Infarction) Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Cerebral Infarction (Brain Infarction) Therapeutics Development 16
Cerebral Infarction (Brain Infarction) – Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Combination Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
Clopidogrel + Aspirin - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
hydroxyurea - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Umbilical Cord Mesenchymal Stem Cell Transplantation - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
AP-102 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Autologous Bone Marrow Derived Mesenchymal Stem Cells - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Human Serum Albumin - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Cerebral Infarction (Brain Infarction) Therapeutics – Drug Profile Updates 28
Cerebral Infarction (Brain Infarction) Therapeutics – Discontinued Products 29
Cerebral Infarction (Brain Infarction) Therapeutics - Dormant Products 30
Cerebral Infarction (Brain Infarction) – Product Development Milestones 31
Featured News & Press Releases 31
Sep 28, 2012: Mitsubishi Tanabe Pharma And Kyowa Hakko File Joint Application For Time-window Extension Of Thrombolytic Agents Grtpa And Activacin 31
Apr 27, 2010: Asahi Kasei Pharma Announces Preliminary Results From Phase III Clinical Study Of AT-877 For Acute Cerebral Infarction 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33

List of Tables
Number of Products Under Development for Cerebral Infarction (Brain Infarction), H2 2012 7
Products under Development for Cerebral Infarction (Brain Infarction) – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Assessment by Monotherapy Products, H2 2012 16
Assessment by Combination Products, H2 2012 17
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Stage and Molecule Type, H2 2012 21
Cerebral Infarction (Brain Infarction) Therapeutics – Drug Profile Updates 28
Cerebral Infarction (Brain Infarction) Therapeutics – Discontinued Products 29
Cerebral Infarction (Brain Infarction) Therapeutics – Dormant Products 30

List of Figures
Number of Products under Development for Cerebral Infarction (Brain Infarction), H2 2012 7
Products under Development for Cerebral Infarction (Brain Infarction) – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 16
Assessment by Combination Products, H2 2012 17
Assessment by Route of Administration, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Molecule Type, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 21

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos